Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.54 |
| ▸ | HTR1B | P28222 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL3562 | 0.93 | SLC6A2 (0.63) | SLC6A2SLC6A4HTR1AHTR1DCACNA2D1 | |
| SCHEMBL9995405 | 0.84 | SLC6A4 (0.67) | SLC6A2SLC6A4CACNA2D1HTR1B | |
| Bromide SCHEMBL6726247 | 0.83 | SLC6A4 (0.65) | SLC6A2SLC6A4CACNA2D1HTR1B | |
| SCHEMBL3967638 | 0.83 | SLC6A4 (1.00) | SLC6A2SLC6A4HTR1ACACNA2D1 | |
| SCHEMBL3359634 | 0.83 | SLC6A4 (1.00) | SLC6A2SLC6A4HTR1ACACNA2D1 | |
| SCHEMBL15113755 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4HTR1AHTR1DCACNA2D1 | |
| Hydrochloric Acid SCHEMBL4413256 | 0.82 | SLC6A4 (0.98) | SLC6A2SLC6A4HTR1ACACNA2D1 | |
| SCHEMBL15113751 | 0.81 | SLC6A2 (0.53) | SLC6A2SLC6A4HTR1AHTR1DCACNA2D1 | |
| SCHEMBL23125446 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A4HTR1AHTR1DCACNA2D1 | |
| SCHEMBL3592 | 0.79 | CACNA2D1 (0.76) | SLC6A2SLC6A4HTR1ACACNA2D1HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | claimed |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2007-12-06 | — | — | US | claimed |
| WO-2013088255-A1 | PRODRUGS OF SECONDARY AMINE COMPOUNDS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-06-20 | — | — | WO | disclosed |
| EP-1976846-A2 | PROCESS FOR PREPARING DULOXETINE AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2008-10-08 | — | — | EP | disclosed |
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2007143065-A2 | PROCESS FOR PREPARING DULOXETINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2007-12-06 | — | — | US | disclosed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207923-A1 | Pure DNT-maleate and methods of preparation thereof | DNTT, NCDN, AANAT | SLC6A2 24/4885SLC6A4 6/4885HTR1A 61/4885 |
| US-20070281989-A1 | Process for preparing duloxetine and intermediates thereof | UGT1A4, CYP3A4, CYP4B1 | SLC6A2 105/4885SLC6A4 60/4885HTR1A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.